Professor Paul Bishop CSO
Professor Bishop is Professor of Ophthalmology and Matrix Biology at Manchester's Centre for Ophthalmology and Vision Sciences, Co-Director at the Centre for Advanced Discovery and Experimental Therapeutics (CADET) and Honorary Consultant Ophthalmologist at the Manchester Royal Eye Hospital. Professor Bishop has been leading research into the Opticin protein for more than a decade.
Dr Jim S. Millen Director
Dr Millen is Jim is an experienced pharmaceuticals executive who has held seniorl positions at companies including GSK and Allergan. He is on the board of several biotech companies where he advises on capital raising and partnering activities. Jim qualified as a medical doctor at Cambridge and the Royal London Hospital. He holds an MBA from INSEAD in France.
Opticin Therapeutics is a Manchester, UK based biotech company conducting research into the use of therapeutic proteins for the treatment of human disease.
Its initial focus is on the treatment of eye diseases using the physiologically occurring protein, Opticin, which has been the subject of research by founder Professor Paul Bishop for over 10 years. Opticin Therapeutics is a virtual company, drawing on the extensive research and clinical experience of Professor Bishop as well as that of a research group based at the Institute of Ophthalmology in London, funded by a significant MRC grant.